EVEROLD LONG TERM FOLLOW-UP
ConditionTransplant; Complication, Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Brest
About this trial
Long Term Follow up of EVEROLD study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Informed patients participating to the EVEROLD study
Patient having completed the EVEROLD M12 follow-up visit
Patient agreeing to participate in the observational study
Disqualifiers
Opposition to the use his medical data
Patient under legal protection
Trial population
260 patients previously included in the EVEROLD study
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
260 Participants
are grouped into 3 trial groupsGroup A: Active Comparator: Control
Group B: Experimental: CNI-free
Group C: Experimental: Switch
Trial outcomes
Primary outcomes
1
Patient survival
Patient survival at last follow-up
Time frame
up to 12 years2
Graft survival
Graft survival at last follow-up
Time frame
up to 12 yearsSecondary outcomes
1
Rejection rate
Biopsy proven rejection
Time frame
up to 12 years2
Infection rate
All infections requiring hospitalization
Time frame
up to 12 years3
Major cardiovascular events
Time frame
up to 12 years4
Cancer rate
Skin cancer, solid organ tumor and hematological cancer
Time frame
up to 12 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov